Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.75665
I. Ariyo
Objectives: We performed a planning study to evaluate the dosimetric differences between Volumetric Modulated Arc Therapy (VMAT) and Intensity Modulated Radiation Therapy (IMRT) using simultaneous Integrated Boost (SIB) for prostate cancer cases. Methods: 20 prostate cancer patients scheduled for SIB-VMAT treatment on the Halcyon TM 2.0 linear accelerator were recruited for this study and SIB-IMRT plans were generated for comparison purpose. The pelvic lymph nodes (PTV46), the seminal vesicle (PTV50), and the prostate (PTV60) were simultaneously treated to 46 Gy 50 Gy, and 60 Gy delivered in 20 fractions respectively. Results: SIB-VMAT was better due to its higher (1.41%) CI, lower (2.7%) HI, and lower (26%) GI than SIB-IMRT for PTV60. For PTV50, a higher (7.3%) CI, lower (48%) HI, and a lower (31.73%) GI for SIB-VMAT compared to SIB-IMRT. Also, for PTV46, a higher (9.4%) CI, lower (2.5%) HI, and a lower (16.4%) GI were achieved by SIB-VMAT compared to SIB-IMRT. Conclusion: Better conformal and slightly similar homogeneous dose distribution were noticed in SIB-VMAT plans compared to SIB-IMRT plans. However, SIB-IMRT provided better OARs sparing of the bladder and the femoral heads while SIB-VMAT had better sparing for rectum.
{"title":"Simultaneous Integrated Boost Plan Comparison between Volumetric Modulated Arc Therapy (VMAT) and Intensity Modulated Radiation Therapy (IMRT) for Prostate, Seminal vesicle and Lymph Node Irradiation","authors":"I. Ariyo","doi":"10.14744/ejmo.2022.75665","DOIUrl":"https://doi.org/10.14744/ejmo.2022.75665","url":null,"abstract":"Objectives: We performed a planning study to evaluate the dosimetric differences between Volumetric Modulated Arc Therapy (VMAT) and Intensity Modulated Radiation Therapy (IMRT) using simultaneous Integrated Boost (SIB) for prostate cancer cases. Methods: 20 prostate cancer patients scheduled for SIB-VMAT treatment on the Halcyon TM 2.0 linear accelerator were recruited for this study and SIB-IMRT plans were generated for comparison purpose. The pelvic lymph nodes (PTV46), the seminal vesicle (PTV50), and the prostate (PTV60) were simultaneously treated to 46 Gy 50 Gy, and 60 Gy delivered in 20 fractions respectively. Results: SIB-VMAT was better due to its higher (1.41%) CI, lower (2.7%) HI, and lower (26%) GI than SIB-IMRT for PTV60. For PTV50, a higher (7.3%) CI, lower (48%) HI, and a lower (31.73%) GI for SIB-VMAT compared to SIB-IMRT. Also, for PTV46, a higher (9.4%) CI, lower (2.5%) HI, and a lower (16.4%) GI were achieved by SIB-VMAT compared to SIB-IMRT. Conclusion: Better conformal and slightly similar homogeneous dose distribution were noticed in SIB-VMAT plans compared to SIB-IMRT plans. However, SIB-IMRT provided better OARs sparing of the bladder and the femoral heads while SIB-VMAT had better sparing for rectum.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83347723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.14462
Z. Momenimovahed
Numerous epidemiological studies examining the etiology of ovarian cancer and the role of pregnancy related factors in ovarian cancer has been one of the topics of interest to many researchers. Various articles have only mentioned the link between some risk factors and ovarian cancer, but no study has addressed the various dimensions of this issue to this day. Therefore, due to the important position of ovarian cancer among gynecological cancers, this study was conducted to investigate the pregnancy-related risk factors for ovarian cancer. relationship characteristic cancer, a comprehensive search was car-ried out in English databases as; Medline, Web of Science Core Collection, and Scopus using ovarian cancer (or 'carcinoma of the ovary' or 'ovarian neoplasm' or 'ovarian tumor'), risk factor, pregnancy characteristic terms and a combination of these terms. Full-text, English language, and original articles were included in this study. In total, 35 articles were entered into the study. The relationship between pregnancy related factors and ovarian cancer were studied. Although there was a weak association between some factors such as preterm birth and the risk of ovarian cancer, only the strong protective effect of parity was seen in the articles. The results of this study did not show that pregnancy related factors increase the risk of ovarian cancer. In summary, the findings are inadequate regarding some risk factors such as gender of fetus, multiple pregnancy, placental and fetal weight, parity, miscarriage, preeclampsia, and gestational diabetes, and raised questions for future research. Abstract
许多流行病学研究检查卵巢癌的病因和妊娠相关因素在卵巢癌中的作用已成为许多研究人员感兴趣的话题之一。各种各样的文章只提到了一些风险因素与卵巢癌之间的联系，但迄今为止还没有研究涉及这个问题的各个方面。因此，鉴于卵巢癌在妇科癌症中的重要地位，本研究旨在探讨卵巢癌的妊娠相关危险因素。关系特征癌，在英文数据库中进行了全面检索;Medline, Web of Science Core Collection和Scopus使用卵巢癌(或“卵巢癌”或“卵巢肿瘤”或“卵巢肿瘤”)，风险因素，妊娠特征术语以及这些术语的组合。本研究包括全文、英文和原创文章。总共有35篇文章被纳入研究。探讨妊娠相关因素与卵巢癌的关系。虽然一些因素如早产和卵巢癌风险之间存在微弱的关联，但文章中只看到胎次的强大保护作用。这项研究的结果并没有显示怀孕相关因素会增加患卵巢癌的风险。综上所述，本研究对胎儿性别、多胎妊娠、胎盘及胎儿体重、胎次、流产、子痫前期、妊娠期糖尿病等危险因素的认识不足，为今后的研究提出了一些问题。摘要
{"title":"Is Pregnancy Characteristic Associated with Ovarian Cancer? A Review of the Available Evidence","authors":"Z. Momenimovahed","doi":"10.14744/ejmo.2022.14462","DOIUrl":"https://doi.org/10.14744/ejmo.2022.14462","url":null,"abstract":"Numerous epidemiological studies examining the etiology of ovarian cancer and the role of pregnancy related factors in ovarian cancer has been one of the topics of interest to many researchers. Various articles have only mentioned the link between some risk factors and ovarian cancer, but no study has addressed the various dimensions of this issue to this day. Therefore, due to the important position of ovarian cancer among gynecological cancers, this study was conducted to investigate the pregnancy-related risk factors for ovarian cancer. relationship characteristic cancer, a comprehensive search was car-ried out in English databases as; Medline, Web of Science Core Collection, and Scopus using ovarian cancer (or 'carcinoma of the ovary' or 'ovarian neoplasm' or 'ovarian tumor'), risk factor, pregnancy characteristic terms and a combination of these terms. Full-text, English language, and original articles were included in this study. In total, 35 articles were entered into the study. The relationship between pregnancy related factors and ovarian cancer were studied. Although there was a weak association between some factors such as preterm birth and the risk of ovarian cancer, only the strong protective effect of parity was seen in the articles. The results of this study did not show that pregnancy related factors increase the risk of ovarian cancer. In summary, the findings are inadequate regarding some risk factors such as gender of fetus, multiple pregnancy, placental and fetal weight, parity, miscarriage, preeclampsia, and gestational diabetes, and raised questions for future research. Abstract","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73877500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2021.29249
J. S. Pascual
Intraoperative radiotherapy (IORT) is the delivery of ionizing radiation to the tumor or tumor bed during surgery while the targeted tissue is exposed.[1] In contrast to other radiation modalities such as whole brain radiotherapy (WBRT), external beam radiotherapy (EBRT), and stereotactic radiosurgery (SRS), IORT has the advantages of increased precision and minimal radiation exposure to adjacent normal tissues,[2] thereby minimizing side effects. Because IORT is administered at the time of surgery, there is also the theoretical advantage of preventing tumor cell repopulation by not giving them time to proliferate, as may be the case in post-operative radiotherapy (RT).[3,4] Patient satisfaction and convenience are also improved since the surgery and radiation are performed in the same sitting,[5] potentially decreasing the duration of treatment. Given these advantages, IORT has been used in a wide range of Juan Silvestre G. Pascual,1 Ella Mae D. Cruz-Lim,2 Aveline Marie D. Ylanan,2 Katrina Hannah D. Ignacio,3 Johanna Patricia A. Cañal,2 Kathleen Joy O. Khu1
术中放射治疗(IORT)是指在手术过程中将电离辐射照射到肿瘤或肿瘤床上，同时暴露靶组织与全脑放疗(WBRT)、外束放疗(EBRT)和立体定向放射外科(SRS)等其他放射方式相比，IORT具有精度提高和对邻近正常组织辐射暴露最小的优点，从而最大限度地减少了副作用。由于IORT是在手术时进行的，因此理论上也有优势，即通过不给肿瘤细胞时间增殖来防止肿瘤细胞再生，这可能是术后放疗(RT)的情况。[3,4]由于手术和放疗是在同一坐姿中进行的，因此患者的满意度和便利性也得到了提高，[5]可能缩短了治疗时间。鉴于这些优点，IORT已广泛应用于Juan Silvestre G. Pascual,1 Ella Mae D. Cruz-Lim,2 Aveline Marie D. Ylanan,2 Katrina Hannah D. Ignacio,3 Johanna Patricia a . Cañal,2 Kathleen Joy O. Khu1
{"title":"Treatment Protocols and Outcomes of Intraoperative Radiotherapy for Brain Metastases: A Systematic Review","authors":"J. S. Pascual","doi":"10.14744/ejmo.2021.29249","DOIUrl":"https://doi.org/10.14744/ejmo.2021.29249","url":null,"abstract":"Intraoperative radiotherapy (IORT) is the delivery of ionizing radiation to the tumor or tumor bed during surgery while the targeted tissue is exposed.[1] In contrast to other radiation modalities such as whole brain radiotherapy (WBRT), external beam radiotherapy (EBRT), and stereotactic radiosurgery (SRS), IORT has the advantages of increased precision and minimal radiation exposure to adjacent normal tissues,[2] thereby minimizing side effects. Because IORT is administered at the time of surgery, there is also the theoretical advantage of preventing tumor cell repopulation by not giving them time to proliferate, as may be the case in post-operative radiotherapy (RT).[3,4] Patient satisfaction and convenience are also improved since the surgery and radiation are performed in the same sitting,[5] potentially decreasing the duration of treatment. Given these advantages, IORT has been used in a wide range of Juan Silvestre G. Pascual,1 Ella Mae D. Cruz-Lim,2 Aveline Marie D. Ylanan,2 Katrina Hannah D. Ignacio,3 Johanna Patricia A. Cañal,2 Kathleen Joy O. Khu1","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86888478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Multi-Molecular Fusion to Detect Transcriptomic Signature in Tissue-Specific Cancer","authors":"Saurav Mallik","doi":"10.14744/ejmo.2022.53376","DOIUrl":"https://doi.org/10.14744/ejmo.2022.53376","url":null,"abstract":"DOI: 10.14744/ejmo.2022.53376 EJMO 2022;6(2):156–171","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87407934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.75565
J. F. Val Bernal
We read with great interest and attention the recent paper by De La Parra and co-authors on the sarcomatoid transformation of chromophobe renal cell carcinoma.[1] In the review of the literature, these authors incorporate 10 cases of this uncommon condition including two own cases (their Table 1). However, the article of Akhtar et al.[2] and the work of our group[3] on this kind of tumor are missing.
我们饶有兴趣地阅读了De La Parra等人最近发表的关于憎色肾细胞癌肉瘤样转化的论文[1]。在文献回顾中，这些作者纳入了10例这种不常见的病例，其中包括2例自己的病例(他们的表1)。然而，Akhtar等人[2]的文章和我们组[3]在这类肿瘤上的工作缺失。
{"title":"Sarcomatoid Chromophobe Renal Cell Carcinoma","authors":"J. F. Val Bernal","doi":"10.14744/ejmo.2022.75565","DOIUrl":"https://doi.org/10.14744/ejmo.2022.75565","url":null,"abstract":"We read with great interest and attention the recent paper by De La Parra and co-authors on the sarcomatoid transformation of chromophobe renal cell carcinoma.[1] In the review of the literature, these authors incorporate 10 cases of this uncommon condition including two own cases (their Table 1). However, the article of Akhtar et al.[2] and the work of our group[3] on this kind of tumor are missing.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"239 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89156249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.71721
Anam Khan
{"title":"Development of Cancer in Gall Bladder Polyps Detected on Ultrasound in a High Risk Population","authors":"Anam Khan","doi":"10.14744/ejmo.2022.71721","DOIUrl":"https://doi.org/10.14744/ejmo.2022.71721","url":null,"abstract":"","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84405492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association of MATN-3 and ADIPOQ Polymorphisms with Susceptibility to Knee Osteoarthritis","authors":"A. Hashemzehi","doi":"10.14744/ejmo.2021.23898","DOIUrl":"https://doi.org/10.14744/ejmo.2021.23898","url":null,"abstract":"DOI: 10.14744/ejmo.2021.23898 EJMO 2021;5(4):291–297","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85837667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development of predictive in silico cytotoxic activity model to predict the cytotoxicity of a diverse set of colchicine binding site inhibitors","authors":"K. Ojha","doi":"10.14744/ejmo.2022.44123","DOIUrl":"https://doi.org/10.14744/ejmo.2022.44123","url":null,"abstract":"DOI: 10.14744/ejmo.2022.44123 EJMO 2022;6(2):172–181","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80425450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.25618
Yuxian Teng
Objectives: Targeted agents combined with immune checkpoint inhibitors (ICIs) for advanced hepatocellular carcinoma (HCC) may improve survival for some patients. This study aims to identify the patients who are most likely to benefit from combination therapy. Methods: The study included 45 patients receiving lenvatinib while other 65 patients receiving lenvatinib plus ICIs between January 2019 and August 2020. Clinical and laboratory data were evaluated and compared. Results: The median follow-up was 20.5 months in the lenvatinib and 18.0 months in the combination group. The cor-responding median overall survival was 9.3 and 13.0 months (p=0.004), respectively. Subgroup analyses found that lenvatinib plus ICIs was associated with better overall survival in patients younger than 60 years, males, without MAFLD as well as with BMI <23 kg/m 2 , cirrhosis, HBV infection, total tumor volume ≥982 cm3, tumor burden score of ≥10.4 or α-fetoprotein ≥200 ng/ml. Conclusion: Lenvatinib plus ICIs therapy seems to be more effective in advanced HCC patients with viral etiology, low BMI, or high tumor load. Abstract With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma.
{"title":"Lenvatinib With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma","authors":"Yuxian Teng","doi":"10.14744/ejmo.2022.25618","DOIUrl":"https://doi.org/10.14744/ejmo.2022.25618","url":null,"abstract":"Objectives: Targeted agents combined with immune checkpoint inhibitors (ICIs) for advanced hepatocellular carcinoma (HCC) may improve survival for some patients. This study aims to identify the patients who are most likely to benefit from combination therapy. Methods: The study included 45 patients receiving lenvatinib while other 65 patients receiving lenvatinib plus ICIs between January 2019 and August 2020. Clinical and laboratory data were evaluated and compared. Results: The median follow-up was 20.5 months in the lenvatinib and 18.0 months in the combination group. The cor-responding median overall survival was 9.3 and 13.0 months (p=0.004), respectively. Subgroup analyses found that lenvatinib plus ICIs was associated with better overall survival in patients younger than 60 years, males, without MAFLD as well as with BMI <23 kg/m 2 , cirrhosis, HBV infection, total tumor volume ≥982 cm3, tumor burden score of ≥10.4 or α-fetoprotein ≥200 ng/ml. Conclusion: Lenvatinib plus ICIs therapy seems to be more effective in advanced HCC patients with viral etiology, low BMI, or high tumor load. Abstract With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76127398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：